Atomoxetine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Atomoxetine

Examples of brand names: Strattera [DE]

ATC code: N06BA09

Main use (for orientation): ADHD

Documented research summary

Open-label atomoxetine plus dronabinol combination in 15 people with obstructive sleep apnoea: dose-dependent efficacy signals and approximately one-third discontinued; no randomised tolerability or pharmacokinetic evidence. Atomoxetine studies in cannabis use disorder do not establish specific cannabis interaction causality.

Uncertainties and limitations

PMC10315604 repeatedly inaccessible; abstract read. CBD must not be classified here as a clinically proven strong CYP2D6 inhibitor. Documented individual title/abstract assessment with selected relevant full texts; not an exhaustive worldwide systematic review or independent human specialist approval. Missing data do not establish safety. All 28 cannabinoids are within the search scope, not 28 clinically investigated pairs per drug.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THC (dronabinol) – clinical signals

Finding ID: B0488

Type of result: Null/differentiating finding

Observation: At an intermediate combination level, the apnoea–hypopnoea index decreased, but not significantly at the highest level; approximately one-third discontinued due to possible adverse effects.

Mechanism: Combination of noradrenergic and cannabinoid effects in obstructive sleep apnoea.

Study type: Open-label exploratory human study

Context studied: 15 people, three weeks; atomoxetine/dronabinol 40/2.5 to 80/10 mg.

Clinical interpretation: Limited clinical signal; sample size, multiple exposures or an uncontrolled design restrict causal and quantitative assessment.

Limitations and uncertainties: Not a controlled isolated interaction or pharmacokinetic test; exploratory therapeutic context, not a general safety or treatment recommendation.

Original sources for this finding: The combination of atomoxetine and dronabinol for the treatment of obstructive sleep apnea: a dose-escalating, open-label trial. [VF_P_36805833]

References and access status

[VF_L_D0429] STRATTERA (ATOMOXETINE HYDROCHLORIDE) CAPSULE [ELI LILLY AND COMPANY]

Original source / bibliographic reference

Authors: Marketing authorisation holder; official product information via DailyMed

Year: 2026

Source type: Official medicine information; relevant identity, PK, PD and DDI sections read individually

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VF_P_36805833] The combination of atomoxetine and dronabinol for the treatment of obstructive sleep apnea: a dose-escalating, open-label trial.

Original source / bibliographic reference

Authors: Messineo L, Norman D, Ojile J.

Year: 2023

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.5664/jcsm.10528

PMID: 36805833

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility